Publications by authors named "Tracy Bridges"
Purpose: To achieve reductions in infusion time, infusion sites, and frequency, a prospective, open-label, multicenter, Phase 3 study evaluated the safety, efficacy, and tolerability of subcutaneous immunoglobulin (SCIG) 16.5% (Cutaquig®, Octapharma) at enhanced infusion regimens.
Methods: Three separate cohorts received SCIG 16.
Article Synopsis
- The SARS-CoV-2 pandemic has highlighted the need for deeper research into immune responses for better treatments and vaccines.
- A study screened over 60,000 asymptomatic people in the Southeastern U.S., finding about 3% had positive IgG antibodies against the viral Spike protein, with higher levels linked to better inhibition of ACE2 binding.
- Compared to asymptomatic individuals, SARS-CoV-2 symptomatic patients showed lower antibody responses and less effective inhibition of ACE2, suggesting that healthy individuals can generate strong immune responses without showing symptoms.
Background: Many children with asthma continue to experience symptoms despite available therapies.
Objective: This study evaluated the efficacy and safety of omalizumab, a humanized anti-IgE mAb, in children with moderate-to-severe persistent allergic (IgE-mediated) asthma that was inadequately controlled despite treatment with medium-dose or high-dose inhaled corticosteroids (ICSs) with or without other controller medications.
Methods: A randomized, double-blind, placebo-controlled trial enrolled children age 6 to <12 years with perennial allergen sensitivity and history of exacerbations and asthma symptoms despite at least medium-dose ICSs.